Abstract:Abstract Background Current expert-based recommendations suggest that clinical and endoscopic remission should be pursued as treatment targets in ulcerative colitis (UC). However, combined endoscopic and histologic remission may be associated with improved outcomes. Methods Retrospective single-center cohort study including consecutive patients with UC under advanced therapy (biologics and small molecules) with endoscopic and histologic evaluation. We evaluated the rates of hospitalization, surgery, steroid-free remission, and treatment discontinuation after 1-year of follow-up according to the type of remission. Endoscopic remission was defined as a Mayo endoscopic subscore of 0. Histologic remission was defined as the absence of ulcers, erosions and neutrophils in the lamina propria. Results One hundred and six patients were included. Thirty-five patients (33.0%) achieved combined endoscopic and histologic remission, 21 patients (19.8%) endoscopic but not histologic remission and 50 patients (47.2%) did not achieve endoscopic remission. At the end of 1-year, 85 patients (79.4%) achieved steroid-free remission, 14 (13.0%) required hospitalization, 4 (3.7%) surgery, 15 (14.1%) discontinued treatment. A compound outcome was reached by 31 (29.2%) patients. In multivariate analysis including age at diagnosis, age at biologic, type of advanced treatment, disease duration, immunomodulation, previous biologic exposure and type of remission, only the type of remission was associated with a lower chance of reaching any unfavourable outcome (reference no remission) - combined endoscopic and histologic remission (OR 0.162 95%CI 0.05-0.528, P=0.003) and isolated endoscopic remission (OR 0.286 95%CI 0.084-0.971, P=0.045). Kaplan-Meier analysis showed longer outcome-free survival in patients with combined endoscopic and histologic remission. Conclusion Achieving combined endoscopic and histologic remission is associated with better clinical outcomes after 1 year of advanced treatment compared to no remission. However, we could not confirm a significant advantage of combined endoscopic and histologic remission over endoscopic remission alone.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: when using advanced therapies (such as biologics and small - molecule drugs) to treat ulcerative colitis (UC), whether achieving endoscopic and histological remission is associated with better clinical outcomes. Specifically, the researchers hope to determine whether combined endoscopic and histological remission can bring better clinical results by evaluating the impact of different types of remission (including combined endoscopic and histological remission, endoscopic - only remission, and failure to achieve endoscopic remission) on patients' hospitalization, surgery, steroid - free remission, and treatment discontinuation. ### Research Background Currently, based on expert opinions, clinical and endoscopic remission should be pursued as treatment goals in the treatment of ulcerative colitis. However, combined endoscopic and histological remission may be associated with a better prognosis. ### Methods This is a retrospective single - center cohort study. UC patients who were continuously treated with advanced therapies (biologics and small - molecule drugs) were included and underwent endoscopic and histological evaluations. The study evaluated the hospitalization rate, surgery rate, steroid - free remission rate, and treatment discontinuation rate of patients within a 1 - year follow - up period according to the remission type (combined endoscopic and histological remission, endoscopic - only remission, or failure to achieve endoscopic remission). - **Endoscopic remission** was defined as a Mayo endoscopic sub - score of 0. - **Histological remission** was defined as no ulcers, no erosions, and no neutrophil infiltration in the lamina propria of the mucosa. ### Results A total of 106 patients were included: - 35 patients (33.0%) achieved combined endoscopic and histological remission, - 21 patients (19.8%) achieved endoscopic - only remission but did not achieve histological remission, - 50 patients (47.2%) did not achieve endoscopic remission. At the end of the 1 - year follow - up: - 85 patients (79.4%) achieved steroid - free remission, - 14 patients (13.0%) required hospitalization, - 4 patients (3.7%) required surgery, - 15 patients (14.1%) discontinued treatment, - 31 patients (29.2%) reached the composite endpoint. Multivariate analysis showed that only the remission type was significantly associated with the incidence of adverse outcomes (the reference group was failure to achieve any remission): - Combined endoscopic and histological remission (odds ratio [OR] = 0.162, 95% confidence interval [CI] = 0.05 - 0.528, \(P = 0.003\)) - Endoscopic - only remission (OR = 0.286, 95% CI = 0.084 - 0.971, \(P = 0.045\)) Kaplan - Meier analysis showed that patients with combined endoscopic and histological remission had a longer event - free survival period. ### Conclusions Compared with failure to achieve any remission, achieving combined endoscopic and histological remission is associated with better clinical outcomes. However, the study failed to confirm that combined endoscopic and histological remission has a significant advantage over endoscopic - only remission. Through the above analysis, this study aims to explore whether combined endoscopic and histological remission can provide better clinical effects in UC patients, thereby providing a basis for future treatment strategies.

P254 Outcomes of endoscopic and histologic remission in ulcerative colitis under advanced therapy

P471 Tight control strategy improves combined histologic and endoscopic remission in ulcerative colitis

P577 Histological Remission Leads to Less Endoscopic Flare-up in Moderate-to-Severe, Biologics Experienced Ulcerative Colitis Patients: A Comprehensive Retrospective Cohort Study

Impact of completely histological remission on reducing flare-ups in moderate-to-severe, biologics-experienced ulcerative colitis patients with endoscopic remission

DOP21 Histo-endoscopic remission (HEMR) Predicts Future Relapse in Patients with Ulcerative Colitis and is Associated with Lower Colectomy Risk

P246 Histologic remission is an important therapeutic target in patients who achieve endoscopic remission of ulcerative colitis

P594 One-year success rates of targeted therapy in Ulcerative Colitis patients revisited

P879 Comparative Efficacy of Biologics and Small Molecule Therapies for the Induction and Maintenance of Endoscopic and Histological Remission in Ulcerative Colitis: A Systematic Review and Network Meta-analysis

P935 Remission rates of biologics and small molecules in extension studies of moderate to severe Ulcerative Colitis; A systematic review and Network Meta-analysis

Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study

Histologic improvement predicts endoscopic remission in patients with ulcerative colitis

Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials

Network Meta‐Analysis: Histologic and Histo‐Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis

P600 Efficacy of different modalities of faecal microbiota transplantation to induce clinical remission in patients with ulcerative colitis: a systematic review and network meta-analysis

P330 Ultrasound remission after biologic induction predicts long-term endoscopic remission in Crohn’s disease

P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study

P386 Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UC-RGENCY study

Rapidly Achieving Clinical Remission in Ulcerative Colitis Indicates Better Endoscopic and Histological Outcomes.

P647 Effectiveness of combined treatment with two biologics or advanced molecules in inflammatory bowel disease

P1171 The impact of biological and small molecule therapy on time to colonic resection and cancer rates in patients with Ulcerative Colitis

Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis—An Exploratory Study to Define Deep Remission